ClinicalTrials.gg
CompletedNCT03503318RISEUpdated Mar 10, 2023Results posted

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

A Phase 3 interventional study of TV-46000 and Placebo in Schizophrenia, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 81 sites in 2 countries. Open to participants aged 13 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-10.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
544
Allocation
Randomized
Ages
13 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
8th of 123
544 · median 100
Started
2018
with 4 others
Phase 3
34 of 127
2 open now
Registered
109th of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 8th largest by enrollment of the 123 interventional ones that give a count, is one of 5 that started in 2018, is one of 34 in phase 3, and was the 109th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent participants with schizophrenia. The study will include male and female participants, 13 to 65 years of age, who have a confirmed diagnosis of schizophrenia, are clinically stable, and are eligible for risperidone treatment

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
13 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a diagnosis of schizophrenia for >1 year and has had ≥1 episode of relapse in the last 24 months.
  • The participant has been responsive to an antipsychotic treatment (other than clozapine) in the past year based on discussions with family members or healthcare professionals.
  • The participant has a stable place of residence for the previous 3 months before screening, and changes in residence are not anticipated over the course of study participation.
  • The participant has no significant life events that could affect study outcomes expected throughout the period of study participation.
  • Women of and sexually-active female adolescents must agree not to try to become pregnant, and, unless they have exclusively same-sex partners, must agree to use a highly effective method of , and agree to continue use of this method beginning 1 month before the first administration of study drugs and for the duration of the study and for 120 days after the last injection of study drug.
  • The participant, if adult or adolescent male, is surgically sterile, or, if capable of producing offspring, or has exclusively same-sex partners or is currently using an approved method of birth control and agrees to the continued use of this method for the duration of the study (and for 120 days after the last dose of study drug). Male participants with sex partners who are women of childbearing potential must use condoms even if surgically sterile

    • Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • The participant has a current , 5th Edition (DSM-5) diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, or amnestic or other cognitive disorders, or borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • The participant is currently on clozapine or received electroconvulsive therapy in the last 12 months.
  • The participant has a history of epilepsy or seizures, neuroleptic malignant syndrome, tardive dyskinesia, or other medical condition that would expose the participant to undue risk.
  • The participant has a positive serology for (HIV)-1, HIV-2, surface antigen, and/or .
  • The participant has current or history of known to risperidone or any of the of TV-46000 or the oral formulation of risperidone used in the stabilization phase.
  • The participant has a substance use disorder, including alcohol and benzodiazepines but excluding nicotine and caffeine.
  • The participant has previously participated in a Teva-sponsored clinical study with TV-46000.
  • The participant is a pregnant or lactating female.
  • The participant has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery).
  • The participant has used an drug within 3 months prior to screening or has participated in a non-drug clinical trial within 30 days prior to screening.

    • Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
544 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.

    Drug: Placebo

  • Experimental
    TV-46000 q1m

    Participants will receive an SC injection of TV-46000 at baseline and q4w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 milligrams (mg)/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.

    Drug: TV-46000

  • Experimental
    TV-46000 q2m

    Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.

    Drug: TV-46000 · Drug: Placebo

Interventions

  • TV-46000 will be administered per dose and schedule specified in the arm.

    Also known as: Risperidone

  • DrugPlacebo

    Placebo matching to TV-46000 will be administered per schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set

    Relapse was defined as 1 or more of the following items: • Clinical Global Impression-Improvement (CGI-I) of ≥5, and - an increase of any of the 4 Positive and Negative Syndrome Scale (PANSS) items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • Clinical Global Impression-Severity of Suicidality (CGI-SS) of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (number of participants with impending relapse).

    Time frame: From randomization up to 108 weeks

Secondary outcomes

  1. Time to Impending Relapse (Number of Participants With Impending Relapse) for Extended ITT [eITT] Analysis Set

    Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adults and adolescents) (number of participants with impending relapse).

    Time frame: From randomization up to 108 weeks

  2. Proportion of Participants With Impending Relapse

    Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Impending relapse rate at Week 24 was estimated using the Kaplan-Meier product estimate.

    Time frame: Week 24

  3. Number of Participants Who Maintain Stability at the Endpoint

    Stability is defined as meeting all of the following criteria for at least 4 consecutive weeks: outpatient status; PANSS total score ≤80; minimal presence of specific psychotic symptoms on the PANSS, as measured by a score of ≤4 on each of the following items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content; Clinical Global Impression of Severity (CGI-S) score ≤4 (moderately ill); and CGI-SS score ≤2 (mildly suicidal) on Part 1 and ≤5 (minimally worsened) on Part 2. The last valid participant assessment was used as the endpoint.

    Time frame: At the endpoint (up to 108 weeks)

  4. Number of Participants Achieving Remission at the Endpoint

    The remission was achieved for participants who did not relapse during the study and for over a period of at least 6 months preceding the endpoint, maintained scores of = 3 on each of the 8 specific PANSS items: P1 (delusions), G9 (unusual thought content), P3 (hallucinatory behavior), P2 (conceptual disorganization), G5 (mannerisms/posturing), N1 (blunted affect), N4 (social withdrawal), and N6 (lack of spontaneity). The last valid participant assessment was used as the endpoint.

    Time frame: At Endpoint (up to 108 weeks)

  5. Observed Rate of Impending Relapse (Number of Participants With Impending Relapse) at the Endpoint

    Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Observed rate of impending relapse was calculated as the number of participants who relapsed by endpoint divided by the number of participants in each treatment group, using the last valid participant assessment as the endpoint.

    Time frame: At the Endpoint (up to 108 weeks)

  6. Time to Impending Relapse (Number of Participants With Impending Relapse) in the Adolescent Participants

    Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adolescents) (number of participants with impending relapse).

    Time frame: From randomization up to 108 weeks

  7. Change From Baseline in Drug Attitudes Inventory 10-item Version (DAI-10) Total Score at the Endpoint and End of Treatment

    The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. The DAI-10 contains 6 items (1, 3, 4, 7, 9, and 10) that a participant who was fully adherent to the prescribed medication answered as "True" and 4 items (2, 5, 6, and 8) that a participant who was fully adherent to the prescribed medication answered as "False." A correct answer was scored +1 and an incorrect answer was scored -1. The total score was the sum of pluses and minuses, which ranged from -10 to 10 in increments of 2. A positive total score indicated a positive subjective response (compliant) and a negative total score indicated a negative subjective response (non-compliance). Higher scores denoted better compliance. The last valid participant assessment was used as the endpoint.

    Time frame: Baseline, endpoint and end of treatment (up to Week 108)

  8. Change From Baseline in Schizophrenia Quality of Life Scale (SQLS) Total Score at the Endpoint and End of Treatment

    The SQLS comprises 33 items categorized in 2 domains: psychosocial feelings (20 items) and cognition and vitality (13 items). The items were scored on a 5-point scale (1 - never, 2 - rarely, 3 - sometimes, 4 - often, 5 - always). Individual domain and total scores were standardized by scoring algorithm to a 0 (best health status) to 100 (worst health status) scale, with higher scores indicating comparatively lower quality of life. The last valid participant assessment was used as the endpoint.

    Time frame: Baseline, endpoint and end of treatment (up to Week 108)

  9. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring after the first dose of the study drug until 120 days after the last dose of study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: From randomization up to 120 days after last dose of study drug (up to Week 125)

  10. Change From Baseline in Total Abnormal Involuntary Movement Scale (AIMS) Score at the End of Treatment

    The AIMS is a 14-item scale that includes assessments of orofacial movements, extremity and truncal dyskinesia, examiner's judgment of global severity, subjective measures of awareness of movements and distress, and a yes/no assessment of problems concerning teeth and/or dentures. Total AIMS score is a sum of item 1 through 7. Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 0 (no dyskinesia) to 4 (severe dyskinesia) scale. Total AIMS score for Items 1-7 ranged from 0 to 28; with higher scores indicating greater severity of the condition.

    Time frame: Baseline, end of treatment (up to 108 weeks)

  11. Change From Baseline in Simpson-Angus Scale (SAS) Mean Score at the End of Treatment

    The SAS is a 10-item instrument for the assessment of neuroleptic-induced parkinsonism. The items on the scale include measurements of hypokinesia, rigidity, glabellar reflex, tremor, and salivation. Each item was rated on a 5-point scale (0 \[None/Normal\] to 4 \[Extreme/Severe\]). The mean score was calculated by adding the individual item scores and dividing by 10. The total mean score ranged from 0-4, with a higher score indicating greater severity of symptoms.

    Time frame: Baseline, end of treatment (up to 108 weeks)

  12. Change From Baseline in Total Barnes Akathisia Rating Scale (BARS) Score at the End of Treatment

    The BARS is an instrument that assesses the severity of drug-induced akathisia. The BARS includes 3 items for rating objective restless movements, subjective restlessness, and any subjective distress associated with akathisia that were scored on a 4-point scale of 0 (normal/no distress) to 3 (constant restlessness/severe distress). Total score was the sum of scores of each item and ranged from 0-9, with higher scores indicating greater severity of akathisia.

    Time frame: Baseline, end of treatment (up to 108 weeks)

  13. Number of Participants Reporting Suicidal Behavior and Suicidal Ideation Using Columbia-Suicide Severity Rating Scale (C-SSRS) at Baseline and Post-Baseline

    The C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior was defined as a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation was defined as a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.

    Time frame: Baseline, post-baseline (up to 108 weeks)

  14. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Score at the End of Treatment

    The CDSS is specifically designed to assess the level of depression separate from the positive, negative, and EPS in schizophrenia. This clinician-administered instrument consists of 9 items, each rated on a 4-point scale from 0 (absent) to 3 (severe) that were added together to form the total CDSS depression score of the participant. The total score ranged from 0-27, with higher scores indicating greater severity of the condition.

    Time frame: Baseline, end of treatment (up to 108 weeks)

  15. Change From Baseline in Clinical Global Impression-Severity of Suicidality (CGI-SS) Score at the End of Treatment

    The CGI-SS scale provides an overall clinician-rated assessment of the risk of suicidality. The CGI-SS consists of a 5-point scale in Part 1 (the most severe level of suicidality experience) ranging from 1 (not at all suicidal) to 5 (attempted suicide) and a 7-point scale in Part 2 (change in participant suicidality) ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Baseline, end of treatment (up to 108 weeks)

  16. Plasma Concentration of Risperidone, 9-OH-risperidone, and Total Active Moiety (Sum of Risperidone and 9-OH-risperidone)

    Time frame: 1 hour prior to dosing at Baseline (Day 1) and at the end of treatment visit (up to 108 weeks)

07

Results

Posted Dec 9, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboTV-46000 q1mTV-46000 q2m
Started181183180
Received at least 1 dose of study drug179183180
Completed142144140
Not completed393940
Withdrew: Death104
Withdrew: Adverse event342
Withdrew: Withdrawal by subject121716
Withdrew: Protocol violation503
Withdrew: Lost to follow-up171512
Withdrew: Other than specified133

Outcome measures

PrimaryTime to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set

Relapse was defined as 1 or more of the following items: • Clinical Global Impression-Improvement (CGI-I) of ≥5, and - an increase of any of the 4 Positive and Negative Syndrome Scale (PANSS) items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • Clinical Global Impression-Severity of Suicidality (CGI-SS) of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (number of participants with impending relapse).

Time frame:
From randomization up to 108 weeks
Reported as:
Count of participants · Participants
Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set
ParticipantsPlaceboTV-46000 q1mTV-46000 q2m
Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set531323
Statistical analysis
  • Placebo vs TV-46000 q1m · Log Rank · p = <0.0001 (Threshold for significance at 0.05 level.) · Hazard ratio (hr): 0.200 · 95% CI 0.109 to 0.367
  • Placebo vs TV-46000 q2m · Log Rank · p = <0.0001 (Threshold for significance at 0.05 level.) · Hazard ratio (hr): 0.375 · 95% CI 0.227 to 0.618
SecondaryTime to Impending Relapse (Number of Participants With Impending Relapse) for Extended ITT [eITT] Analysis Set

Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adults and adolescents) (number of participants with impending relapse).

Time frame:
From randomization up to 108 weeks
Reported as:
Count of participants · Participants
Time to Impending Relapse (Number of Participants With Impending Relapse) for Extended ITT [eITT] Analysis Set
ParticipantsPlaceboTV-46000 q1mTV-46000 q2m
Time to Impending Relapse (Number of Participants With Impending Relapse) for Extended ITT [eITT] Analysis Set531324
SecondaryProportion of Participants With Impending Relapse

Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Impending relapse rate at Week 24 was estimated using the Kaplan-Meier product estimate.

Time frame:
Week 24
Reported as:
Number · proportion of participants
Proportion of Participants With Impending Relapse
proportion of participantsPlaceboTV-46000 q1mTV-46000 q2m
Proportion of Participants With Impending Relapse0.28 (0.205 to 0.347)0.07 (0.03 to 0.109)0.11 (0.065 to 0.165)
SecondaryNumber of Participants Who Maintain Stability at the Endpoint

Stability is defined as meeting all of the following criteria for at least 4 consecutive weeks: outpatient status; PANSS total score ≤80; minimal presence of specific psychotic symptoms on the PANSS, as measured by a score of ≤4 on each of the following items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content; Clinical Global Impression of Severity (CGI-S) score ≤4 (moderately ill); and CGI-SS score ≤2 (mildly suicidal) on Part 1 and ≤5 (minimally worsened) on Part 2. The last valid participant assessment was used as the endpoint.

Time frame:
At the endpoint (up to 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Maintain Stability at the Endpoint
ParticipantsPlaceboTV-46000 q1mTV-46000 q2m
Number of Participants Who Maintain Stability at the Endpoint110159143
SecondaryNumber of Participants Achieving Remission at the Endpoint

The remission was achieved for participants who did not relapse during the study and for over a period of at least 6 months preceding the endpoint, maintained scores of = 3 on each of the 8 specific PANSS items: P1 (delusions), G9 (unusual thought content), P3 (hallucinatory behavior), P2 (conceptual disorganization), G5 (mannerisms/posturing), N1 (blunted affect), N4 (social withdrawal), and N6 (lack of spontaneity). The last valid participant assessment was used as the endpoint.

Time frame:
At Endpoint (up to 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants Achieving Remission at the Endpoint
ParticipantsPlaceboTV-46000 q1mTV-46000 q2m
Number of Participants Achieving Remission at the Endpoint303942
SecondaryObserved Rate of Impending Relapse (Number of Participants With Impending Relapse) at the Endpoint

Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Observed rate of impending relapse was calculated as the number of participants who relapsed by endpoint divided by the number of participants in each treatment group, using the last valid participant assessment as the endpoint.

Time frame:
At the Endpoint (up to 108 weeks)
Reported as:
Count of participants · Participants
Observed Rate of Impending Relapse (Number of Participants With Impending Relapse) at the Endpoint
ParticipantsPlaceboTV-46000 q1mTV-46000 q2m
Observed Rate of Impending Relapse (Number of Participants With Impending Relapse) at the Endpoint531323
SecondaryTime to Impending Relapse (Number of Participants With Impending Relapse) in the Adolescent Participants

Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adolescents) (number of participants with impending relapse).

Time frame:
From randomization up to 108 weeks
Reported as:
Count of participants · Participants
Time to Impending Relapse (Number of Participants With Impending Relapse) in the Adolescent Participants
ParticipantsPlaceboTV-46000 q1mTV-46000 q2m
Time to Impending Relapse (Number of Participants With Impending Relapse) in the Adolescent Participants——1
SecondaryChange From Baseline in Drug Attitudes Inventory 10-item Version (DAI-10) Total Score at the Endpoint and End of Treatment

The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. The DAI-10 contains 6 items (1, 3, 4, 7, 9, and 10) that a participant who was fully adherent to the prescribed medication answered as "True" and 4 items (2, 5, 6, and 8) that a participant who was fully adherent to the prescribed medication answered as "False." A correct answer was scored +1 and an incorrect answer was scored -1. The total score was the sum of pluses and minuses, which ranged from -10 to 10 in increments of 2. A positive total score indicated a positive subjective response (compliant) and a negative total score indicated a negative subjective response (non-compliance). Higher scores denoted better compliance. The last valid participant assessment was used as the endpoint.

Time frame:
Baseline, endpoint and end of treatment (up to Week 108)
Reported as:
Mean · units on a scale
Change From Baseline in Drug Attitudes Inventory 10-item Version (DAI-10) Total Score at the Endpoint and End of Treatment
units on a scalePlaceboTV-46000 q1mTV-46000 q2m
Baseline6.1 ± 3.235.8 ± 3.635.7 ± 3.13
Change at the Endpoint-0.8 ± 3.880.1 ± 3.34-0.3 ± 3.65
Change at the End of Treatment-0.9 ± 3.420.3 ± 2.840.3 ± 3.51
SecondaryChange From Baseline in Schizophrenia Quality of Life Scale (SQLS) Total Score at the Endpoint and End of Treatment

The SQLS comprises 33 items categorized in 2 domains: psychosocial feelings (20 items) and cognition and vitality (13 items). The items were scored on a 5-point scale (1 - never, 2 - rarely, 3 - sometimes, 4 - often, 5 - always). Individual domain and total scores were standardized by scoring algorithm to a 0 (best health status) to 100 (worst health status) scale, with higher scores indicating comparatively lower quality of life. The last valid participant assessment was used as the endpoint.

Time frame:
Baseline, endpoint and end of treatment (up to Week 108)
Reported as:
Mean · units on a scale
Change From Baseline in Schizophrenia Quality of Life Scale (SQLS) Total Score at the Endpoint and End of Treatment
units on a scalePlaceboTV-46000 q1mTV-46000 q2m
Baseline34.0 ± 16.0633.1 ± 16.7934.2 ± 15.70
Change at the Endpoint0.9 ± 14.24-4.5 ± 14.31-4.1 ± 15.23
Change at the End of Treatment-2.3 ± 13.26-7.2 ± 13.79-7.3 ± 12.30
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring after the first dose of the study drug until 120 days after the last dose of study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
From randomization up to 120 days after last dose of study drug (up to Week 125)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboTV-46000 q1mTV-46000 q2m
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)92111121
SecondaryChange From Baseline in Total Abnormal Involuntary Movement Scale (AIMS) Score at the End of Treatment

The AIMS is a 14-item scale that includes assessments of orofacial movements, extremity and truncal dyskinesia, examiner's judgment of global severity, subjective measures of awareness of movements and distress, and a yes/no assessment of problems concerning teeth and/or dentures. Total AIMS score is a sum of item 1 through 7. Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 0 (no dyskinesia) to 4 (severe dyskinesia) scale. Total AIMS score for Items 1-7 ranged from 0 to 28; with higher scores indicating greater severity of the condition.

Time frame:
Baseline, end of treatment (up to 108 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in Total Abnormal Involuntary Movement Scale (AIMS) Score at the End of Treatment
units on a scalePlaceboTV-46000 q1mTV-46000 q2m
Baseline0.4 ± 1.300.5 ± 1.830.2 ± 0.79
Change at the End of Treatment0.0 ± 1.100.1 ± 0.620.1 ± 1.00
SecondaryChange From Baseline in Simpson-Angus Scale (SAS) Mean Score at the End of Treatment

The SAS is a 10-item instrument for the assessment of neuroleptic-induced parkinsonism. The items on the scale include measurements of hypokinesia, rigidity, glabellar reflex, tremor, and salivation. Each item was rated on a 5-point scale (0 \[None/Normal\] to 4 \[Extreme/Severe\]). The mean score was calculated by adding the individual item scores and dividing by 10. The total mean score ranged from 0-4, with a higher score indicating greater severity of symptoms.

Time frame:
Baseline, end of treatment (up to 108 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in Simpson-Angus Scale (SAS) Mean Score at the End of Treatment
units on a scalePlaceboTV-46000 q1mTV-46000 q2m
Baseline0.07 ± 0.1370.09 ± 0.1950.06 ± 0.134
Change at the End of Treatment0.04 ± 0.1340.02 ± 0.2110.00 ± 0.102
SecondaryChange From Baseline in Total Barnes Akathisia Rating Scale (BARS) Score at the End of Treatment

The BARS is an instrument that assesses the severity of drug-induced akathisia. The BARS includes 3 items for rating objective restless movements, subjective restlessness, and any subjective distress associated with akathisia that were scored on a 4-point scale of 0 (normal/no distress) to 3 (constant restlessness/severe distress). Total score was the sum of scores of each item and ranged from 0-9, with higher scores indicating greater severity of akathisia.

Time frame:
Baseline, end of treatment (up to 108 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in Total Barnes Akathisia Rating Scale (BARS) Score at the End of Treatment
units on a scalePlaceboTV-46000 q1mTV-46000 q2m
Baseline0.2 ± 0.630.1 ± 0.390.2 ± 0.57
Change at the End of Treatment-0.1 ± 0.560.0 ± 0.51-0.1 ± 0.56
SecondaryNumber of Participants Reporting Suicidal Behavior and Suicidal Ideation Using Columbia-Suicide Severity Rating Scale (C-SSRS) at Baseline and Post-Baseline

The C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior was defined as a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation was defined as a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.

Time frame:
Baseline, post-baseline (up to 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants Reporting Suicidal Behavior and Suicidal Ideation Using Columbia-Suicide Severity Rating Scale (C-SSRS) at Baseline and Post-Baseline
ParticipantsPlaceboTV-46000 q1mTV-46000 q2m
Baseline: Suicidal behavior003
Baseline: Suicidal ideation657
Post-baseline: Suicidal behavior311
Post-baseline: Suicidal ideation12712
SecondaryChange From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Score at the End of Treatment

The CDSS is specifically designed to assess the level of depression separate from the positive, negative, and EPS in schizophrenia. This clinician-administered instrument consists of 9 items, each rated on a 4-point scale from 0 (absent) to 3 (severe) that were added together to form the total CDSS depression score of the participant. The total score ranged from 0-27, with higher scores indicating greater severity of the condition.

Time frame:
Baseline, end of treatment (up to 108 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Score at the End of Treatment
units on a scalePlaceboTV-46000 q1mTV-46000 q2m
Baseline1.6 ± 2.141.3 ± 1.921.5 ± 1.93
Change at the End of Treatment-0.4 ± 2.72-0.3 ± 1.39-0.8 ± 2.24
SecondaryChange From Baseline in Clinical Global Impression-Severity of Suicidality (CGI-SS) Score at the End of Treatment

The CGI-SS scale provides an overall clinician-rated assessment of the risk of suicidality. The CGI-SS consists of a 5-point scale in Part 1 (the most severe level of suicidality experience) ranging from 1 (not at all suicidal) to 5 (attempted suicide) and a 7-point scale in Part 2 (change in participant suicidality) ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Baseline, end of treatment (up to 108 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression-Severity of Suicidality (CGI-SS) Score at the End of Treatment
units on a scalePlaceboTV-46000 q1mTV-46000 q2m
The most severe level of suicidality experience at Baseline1.0 ± 0.001.0 ± 0.001.0 ± 0.00
Change in participant suicidality at the End of Treatment4.0 ± 0.004.0 ± 0.004.0 ± 0.00
SecondaryPlasma Concentration of Risperidone, 9-OH-risperidone, and Total Active Moiety (Sum of Risperidone and 9-OH-risperidone)
Time frame:
1 hour prior to dosing at Baseline (Day 1) and at the end of treatment visit (up to 108 weeks)
Reported as:
Mean · ng/mL
Plasma Concentration of Risperidone, 9-OH-risperidone, and Total Active Moiety (Sum of Risperidone and 9-OH-risperidone)
ng/mLPlaceboTV-46000 q1mTV-46000 q2m
Risperidone at Baseline4.694 (0.050 to 58.376)6.452 (0.050 to 97.935)5.364 (0.05 to 125.524)
Risperidone at the End of Treatment1.323 (0.050 to 47.683)13.215 (0.050 to 136.184)8.838 (0.05 to 75.95)
9-OH-Risperidone at Baseline14.965 (0.150 to 84.471)18.473 (0.15 to 105.26)15.187 (0.15 to 107.316)
9-OH-Risperidone at the End of Treatment2.982 (0.150 to 40.730)26.202 (0.15 to 101.354)17.778 (0.15 to 88.333)
Total Active Moiety at Baseline19.060 (0.050 to 95.595)24.200 (0.050 to 134.202)19.945 (0.05 to 172.763)
Total Active Moiety at the End of Treatment4.078 (0.050 to 62.621)38.429 (0.050 to 159.498)25.947 (0.05 to 135.823)

Adverse events

Collected over From randomization up to 120 days after last dose of study drug (up to Week 125). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/179 (0.6%)14/179 (7.8%)35/179 (19.6%)
TV-46000 q1m0/183 (0%)8/183 (4.4%)49/183 (26.8%)
TV-46000 q2m4/180 (2.2%)10/180 (5.6%)48/180 (26.7%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlaceboTV-46000 q1mTV-46000 q2m
SchizophreniaPsychiatric disorders4/1790/1832/180
Pelvic abscessInfections and infestations0/711/710/70
Psychotic disorderPsychiatric disorders2/1790/1831/180
Psychotic symptomPsychiatric disorders2/1790/1830/180
Suicidal ideationPsychiatric disorders1/1792/1830/180
Myocardial infarctionCardiac disorders1/1790/1830/180
Pancreatitis acuteGastrointestinal disorders1/1790/1830/180
CholelithiasisHepatobiliary disorders1/1790/1830/180
PneumoniaInfections and infestations1/1790/1830/180
SyncopeNervous system disorders1/1790/1830/180
Most frequent other events
Most frequent other events
EventPlaceboTV-46000 q1mTV-46000 q2m
Injection site noduleGeneral disorders6/17912/18313/180
Weight increasedInvestigations6/17910/18313/180
Injection site painGeneral disorders11/1799/18312/180
InsomniaPsychiatric disorders10/17912/1835/180
HeadacheNervous system disorders10/1799/18311/180
Injection site pruritusGeneral disorders4/17910/1837/180

Baseline characteristics

Extended intent-to-treat (eITT) analysis set included all participants (adults and adolescents) randomized to the double-blind maintenance stage treatment, regardless if they had received treatment or not.

Age, Continuous
Age, Continuous(years)PlaceboTV-46000 q1mTV-46000 q2mTotal
Mean49.2 ± 11.4350.6 ± 10.3048.1 ± 11.0949.3 ± 10.98
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTV-46000 q1mTV-46000 q2mTotal
Female717170212
Male110112110332
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTV-46000 q1mTV-46000 q2mTotal
Hispanic or Latino423936117
Not Hispanic or Latino139144144427
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTV-46000 q1mTV-46000 q2mTotal
Race — White687266206
Race — Black or African American104108110322
Race — Asian4127
Race — Native Hawaiian or Other Pacific Islander1102
Race — Not Reported2103
Race — Other2024
08

Study locations

81 sites
  • Teva Investigational Site 14769
    Little Rock, Arkansas 72211, United States
  • Teva Investigational Site 14796
    Rogers, Arkansas 72758, United States
  • Teva Investigational Site 14811
    Anaheim, California 92805, United States
  • Teva Investigational Site 14794
    Bellflower, California 90706, United States
  • Teva Investigational Site 14776
    Colton, California 92324, United States
  • Teva Investigational Site 14767
    Costa Mesa, California 92626, United States
  • Teva Investigational Site 14802
    Costa Mesa, California 92627, United States
  • Teva Investigational Site 14773
    Culver City, California 90230, United States
  • Teva Investigational Site 14835
    Garden Grove, California 92845, United States
  • Teva Investigational Site 14774
    Glendale, California 91206, United States
  • Teva Investigational Site 14817
    La Habra, California 90631, United States
  • Teva Investigational Site 14771
    Lemon Grove, California 91945, United States
  • Teva Investigational Site 14823
    Long Beach, California 90822, United States
  • Teva Investigational Site 14816
    Montclair, California 91763, United States
  • Teva Investigational Site 14803
    Norwalk, California 90650, United States
  • Teva Investigational Site 14786
    Oakland, California 94607, United States
  • Teva Investigational Site 14797
    Oceanside, California 92054, United States
  • Teva Investigational Site 14827
    Oceanside, California 92056-4515, United States
  • Teva Investigational Site 14777
    Orange, California 92868, United States
  • Teva Investigational Site 14815
    Pico Rivera, California 90660, United States
  • Teva Investigational Site 14812
    Riverside, California 92506, United States
  • Teva Investigational Site 14785
    San Bernardino, California 92408, United States
  • Teva Investigational Site 14818
    San Diego, California 92103, United States
  • Teva Investigational Site 14828
    San Diego, California 92103, United States
  • Teva Investigational Site 14819
    San Marcos, California 92078, United States
  • Teva Investigational Site 14779
    Santa Ana, California 92705, United States
  • Teva Investigational Site 14788
    Torrance, California 90502, United States
  • Teva Investigational Site 14768
    Coral Gables, Florida 33134, United States
  • Teva Investigational Site 14783
    Coral Gables, Florida 33134, United States
  • Teva Investigational Site 14836
    Hallandale Beach, Florida 33009, United States
  • Teva Investigational Site 14787
    Hialeah, Florida 33016, United States
  • Teva Investigational Site 14814
    Hialeah, Florida 33018, United States
  • Teva Investigational Site 14799
    Lauderhill, Florida 33319, United States
  • Teva Investigational Site 14832
    Miami, Florida 33126, United States
  • Teva Investigational Site 14810
    North Miami, Florida 33161, United States
  • Teva Investigational Site 14831
    Orange City, Florida 32763, United States
  • Teva Investigational Site 14806
    Orlando, Florida 32810, United States
  • Teva Investigational Site 14837
    Tampa, Florida 33614, United States
  • Teva Investigational Site 14824
    Atlanta, Georgia 30331, United States
  • Teva Investigational Site 14834
    Columbus, Georgia 31904, United States
  • Teva Investigational Site 14821
    Decatur, Georgia 30030, United States
  • Teva Investigational Site 14770
    Marietta, Georgia 30060, United States
  • Teva Investigational Site 14765
    Chicago, Illinois 60612, United States
  • Teva Investigational Site 14829
    Chicago, Illinois 60640, United States
  • Teva Investigational Site 14805
    Hoffman Estates, Illinois 60169, United States
  • Teva Investigational Site 14825
    Shreveport, Louisiana 71101, United States
  • Teva Investigational Site 14764
    Glen Burnie, Maryland 21061, United States
  • Teva Investigational Site 14820
    New Bedford, Massachusetts 02740, United States
  • Teva Investigational Site 14798
    Saginaw, Michigan 48603, United States
  • Teva Investigational Site 14791
    Saint Louis, Missouri 63109, United States
  • Teva Investigational Site 14813
    Saint Louis, Missouri 63128, United States
  • Teva Investigational Site 14826
    Saint Louis, Missouri 63132, United States
  • Teva Investigational Site 14790
    Saint Louis, Missouri 63141, United States
  • Teva Investigational Site 14809
    Las Vegas, Nevada 89102, United States
  • Teva Investigational Site 14792
    Berlin, New Jersey 08009, United States
  • Teva Investigational Site 14830
    Princeton, New Jersey 08540, United States
  • Teva Investigational Site 14772
    Cedarhurst, New York 11516, United States
  • Teva Investigational Site 14804
    New York, New York 10029, United States
  • Teva Investigational Site 14800
    New York, New York 10032, United States
  • Teva Investigational Site 14784
    New York, New York 10036, United States
  • Teva Investigational Site 14780
    Staten Island, New York 10312, United States
  • Teva Investigational Site 14763
    Cincinnati, Ohio 45219, United States
  • Teva Investigational Site 14782
    Dayton, Ohio 45417, United States
  • Teva Investigational Site 14822
    Oklahoma City, Oklahoma 73112, United States
  • Teva Investigational Site 14789
    Allentown, Pennsylvania 18104, United States
  • Teva Investigational Site 14833
    Norristown, Pennsylvania 19403, United States
  • Teva Investigational Site 14775
    Scranton, Pennsylvania 18503, United States
  • Teva Investigational Site 14793
    Thorndale, Pennsylvania 19372, United States
  • Teva Investigational Site 14778
    Charleston, South Carolina 29407, United States
  • Teva Investigational Site 14781
    Dallas, Texas 75231, United States
  • Teva Investigational Site 14766
    Dallas, Texas 75243, United States
  • Teva Investigational Site 14801
    Houston, Texas 77081, United States
  • Teva Investigational Site 14807
    Irving, Texas 75062, United States
  • Teva Investigational Site 59148
    Bourgas, 8000, Bulgaria
  • Teva Investigational Site 59152
    Kazanlak, 6100, Bulgaria
  • Teva Investigational Site 59151
    Lovech, 5500, Bulgaria
  • Teva Investigational Site 59149
    Novi Iskar, 1282, Bulgaria
  • Teva Investigational Site 59144
    Sofia, 1680, Bulgaria
  • Teva Investigational Site 59154
    Varna, 9000, Bulgaria
  • Teva Investigational Site 59150
    Varna, 9020, Bulgaria
  • Teva Investigational Site 59146
    Vratsa, 3000, Bulgaria
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Sep 2020, 29 months.

Results were first posted in Dec 2021, 1 year 2 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 29 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2018
First posted
Apr 19, 2018
StartActual
Apr 27, 2018
Primary completionActual
Sep 30, 2020
CompletionActual
Dec 3, 2020
Results first posted
Dec 9, 2021
Last update
Mar 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03503318
Responsible party
Sponsor
First posted
Apr 19, 2018
Start date
Apr 27, 2018
Primary completion
Sep 30, 2020
Completion
Dec 3, 2020
Results posted
Dec 9, 2021
Last update
Mar 10, 2023

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion